Overview
Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023.
Research hypothesis:
Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.
Eligibility
Inclusion Criteria:
- All patients undergoing surgery with use of neuromuscular blocking agents at our institution
Exclusion Criteria:
- Incomplete electronic anesthesia record